ArticleMovement disorders : official journal of the Movement Disorder Society2018
Projection of the prevalence of Parkinson's disease in the coming decades: Revisited.
Article in Movement disorders : official journal of the Movement Disorder Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Outcomes following spinal instrumented fusions in patients with parkinson's disease: a systematic review and meta-analysis.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2024Pooled it
- Health economics of Parkinson's disease prevention: why early detection matters in low- and middle-income countries.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Surgical Outcomes of Degenerative Cervical Myelopathy in Patients with Parkinson Disease: A Systematic Review.Global spine journal · 2026Review
- Article
- Mapping the Parkinson's pandemic: Unveiling and addressing the global burden.Journal of Parkinson's disease · 2026Review
- Lived Experiences of Male Caregivers Supporting Individuals with Parkinson's Disease.Healthcare (Basel, Switzerland) · 2026Article
- National implementation of a digital Parkinson's disease screening programme in Thailand: reach, adoption, and real-world performance of the CheckPD app.BMC public health · 2026Article
- An online platform to increase access to gait rehabilitation for underserved Parkinson's disease communities.Journal of Parkinson's disease · 2026Article
- The Burden of Parkinson's Disease Based on the GBD 2021.International journal of public health · 2026Article
- Plasma Levels of Food-Derived Metabolites as Biomarkers of Parkinson's Disease.International journal of molecular sciences · 2025Article
- Parkinson Disease and the Gut: A Primer for Gastroenterologists.The American journal of gastroenterology · 2025Review
- Skeletal MuscleDiagnostics (Basel, Switzerland) · 2025Article
- The global, regional, and National burden of parkinson's disease in 204 countries and territories, 1990-2021: a systematic analysis for the global burden of disease study 2021.BMC public health · 2025Article
- Beyond the Cardio-Renal-Metabolic Axis: Emerging Therapeutic Targets and Novel Mechanisms of Action of Flozins.Journal of clinical medicine · 2025Review
- The Evolving Global Burden of Young-Onset Parkinson's Disease (1990-2021): Regional, Gender, and Age Disparities in the Context of Rising Incidence and Declining Mortality.Brain and behavior · 2025Article
- Development of Positron Emission Tomography Radiotracers for Imaging α-Synuclein Aggregates.Cells · 2025Review
- Article
- Dual stream transformer for medication state classification in Parkinson's disease patients using facial videos.NPJ digital medicine · 2025Article
- Preclinical assessment of a ganglioside-targeted therapy for Parkinson's disease with the first-in-class adaptive peptide AmyP53.Scientific reports · 2025Article
- Projections for prevalence of Parkinson's disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021.BMJ (Clinical research ed.) · 2025Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
objectivePrevious studies have estimated future PD prevalence based on population aging. This study revisits that projection by accounting for the potential impact of declining rates of smoking.
methodsThe age- and gender-stratified smoking prevalence in the United States from 2000 to 2040 were obtained from the U.S. Census Bureau and the U.S. Surgeon General's Smoking Report. PD prevalence was estimated based on population aging with and without an account of the impact of declining smoking rates. Relative risks of 0.56 and 0.78 were applied for current and former smokers, respectively.
resultsAccounting for aging alone, ∼700,000 PD cases are predicted by 2040. After accounting for the declining smoking prevalence, ∼770,000 cases, an increase of ∼10% over the estimate without smoking, is predicted.
conclusionsIf the epidemiological association of smoking and PD is causal, projecting future cases without considering smoking may underestimate disease burden, underscoring the urgency of adequate resource allocation. © 2017 International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.